60.61USD+3.27%Mkt Cap: 3.66B USDP/E: —Last update: 2026-05-22
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead pr…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap3.66B USD
Enterprise Value3.16B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-105.43M USD
Revenue/Share—
Last Price60.61 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-23.84
PEG—
EV/EBITDA-23.68
EV/Revenue—
P/S—
P/B6.10
EPS (TTM)-1.93
EPS (Forward)-2.46
52W Range
10.6462% of range91.00
52W High91.00 USD
52W Low10.64 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.48%
ROA-21.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.21M USD
CapEx (TTM)209.00K USD
FCF Margin—
FCF Yield-1.54%
Net Debt-387.02M USD
Net Debt/EBITDA2.90
Balance Sheet
Debt/Equity0.00
Current Ratio23.76
Quick Ratio23.38
Book Value/Sh9.626 USD
Cash/Share6.447 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateAug 28, 2024
Splits
Last Split1:12
Split DateSep 3, 2024
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)142.17 USD
Target Range100.00 USD – 200.00 USD
# Analysts12
Ownership
Shares Out.60.31M
Float51.00M
Insiders1.36%
Institutions87.87%
Short Interest
Short Ratio3.5d
Short % Float17.87%
Short % Out.11.68%
Shares Short6.99M
Short (prev mo.)4.52M
Technical
SMA 5058.03 (+4.4%)
SMA 20034.10 (+77.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)2.08M
Avg Vol (10d)1.33M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—